When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...

Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Myocardial Infarction.

The rest of Europe could learn from them. Politicians in Brussels are perpetually searching for ways to invigorate the ...

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with ...

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

The Nordic region accounts for about 1 per cent of the world’s gross domestic product and 0.3 per cent of its population. Yet ...

Explore 13 of the most technologically advanced countries leading in innovation, research, and technological development ...